Is Mark Ahn out of prison yet? If he is maybe they can bring him in as a consultant since the new board member worked with him at Galena?

The 2nd to last column is Number of Shares Post-Offering, and for Van Houten it is "-" meaning 0 and for Lonsford it is 15,000. I don't know why you can't understand that they intend to sell the amounts listed.

Don't think you are right. Looks like a simple case of math where he's selling 547,204 shares and will be left with 15K:

Chris Lonsford 562,204 * 319,117 228,087 15,000


Look at Andrew Van Houten for a random example of someone selling all their shares:

Andrew Van Den Houten. 686,273 * 392,156 294,117 *

When I was reviewing SEC documents today looking for the EFFECT it was like a stroll down memory lane. I particularly enjoyed reading the letter the SEC sent to Mulholland questioning certain aspects of the financial statements.

You are right if the SEC does not EFFECT this latest S-3, those 350M shares that were approved will be essentially worthless since there is no exit for buyers.

Good catch. Indeed no notice of EFFECT yet.

Most likely. The paid promoters have been oddly silent the last few months. The last pump was orchestrated by "Pitt" asking the absurd question to Kelly on the June 30, 2022 call about a GSK partnership/buyout. Kelly, to his credit, did not indulge that fantasy, but it did seem strange he had a long winded answer ready about GSK and how they are always looking at acquisitions. Pitt then kept hammering on the message boards that a GSK buyout of Cytodyn was most likely, hence the subsequent unexplained run up in price.

The deluge begins! Prospectus filed; 109M $CYDY shares being sold by stockholders. I thought the baggies said "they won't actually sell their shares, they are just registering them"
Lonsford offering 500K shares, will be left with just 15k.

If you read yesterdays OTCQB Certification document on the otcmarkets website you'd be shocked to see there is only 1 paid promoter now. Yes, the infamous Spokane Mike and Lonsford no longer officially promote. Key word is officially, as Lonsford was on that S-3 registration and he has a lot of shares to dump. So, he may be doing "pro bono" work!

You mean the esteemed doctor with research experience in osteoporosis was not qualified to do HIV and immunology research? Shocking! Just shocking!

Wreckner Bio

The irony is too much. Galena was nailed for failing to disclose paying promoters to hype the stock as the CEO (Ahn) was unloading his shares. Sounds familiar? GOD WILLING Nader suffers the same consequences that Ahn did.

Was Ryan Dunlap placed on the BOD based on a recommendation from Mark Ahn? Remember this old article about "neighbors" Nadar and Mark? Google Mark Ahn to learn about his history.

Neighbors

An HIV BLA will never be filed again. The company declared success in clinical trials, yet has not published data for peer review in a respectable journal. The FDA has refused to look at the data, that is what a BLA rejection means. Instead, the FDA responded with a 20 page letter of fixes that need to be done. Done by a new CRO that had no involvement with the trials since Amarex is being scapegoated to cover management's incompetence.

Its looking more and more likely that Arman was hired simply to excite the longs and get the 350M dilution passed. Not a word out of his mouth recently. He will probably collect his $1.5M in a month or so and bounce like Mahboob did.

Its over. The end stages of the death spiral begin. How long do you think Samsung and Fife will sit around not getting paid?

Saw this elsewhere: "CYDY has approximately AT LEAST 40m of the 350m shares contractually obligated for use outside the placement. 15m for welch warrants 22m for employee equity fund reinstatement, the equivalent of $1.5m to pay arman for doing nothing and equiv to $400k for BOD."

Spotted on ymb: "Cytodyn itself, the fact that it is a biotech without any trials is obviously the biggest issue. This is like a restaurant that has no food to serve."

Nothing to do with it being a BP drug. Everything to do with running proper clinical trials and not taking shortcuts. Something the former twice convicted felon CEO failed to comprehend and also not checked by his nominal boss the bone doc/Chairman of the Board who could only say "back to you nadder" on conference calls.

LOL. Like clockwork when a big dilution is on the horizon and a pump is needed the "analyst articles" start to appear. When will Chris Longsford's come out? Would it be legal for him to pump this when he is listed on the S-3 as having intent to sell shares to the public?

Once the shareholders approve the 350M share dilution, management (not shareholders) would be better off if the holds were not lifted and trials were not run. The burn rate would be much lower and management could continue to pay themselves their salaries without fear of running out of shares.

Why not just ask for a billion shares now to avoid the inevitable hat in hand show in a few months?

I'm just going off what I read here. I thought someone had mentioned that they got access. So they didn't yet and have requested it only? My apologies if so. Hard to keep straight all the legal proceedings involving this company.

Migliariase is still there. Wasn't he part of the financial accounting problems when he was under Mulholland. Kelly is still there; wasn't he chairman of the board when Pourhassan was wrecking the company with his stupidity and greed? Nithya Ray is still there god knows doing what to earn his paycheck; didn't he famously declare he'd leave if Pourhassan ever left? LMAO...all addicted to the compensation here that they'd never get anywhere else!

Nope. The class action lawsuit that was settled last year or in 2020 (I forget off the top of my head) cost the company $5M. So it didn't go nowhere. This class has access to the SEC and DOJ findings so it will be more interesting.

Will Scott read out loud his 46 page book at the conference he attends in October? What data will he present that isn't already known since NASH was a flop?

Just like Mahboob, Arian Colachiis(sp) previously, now Brendan Rae quietly leaves with no fanfare or explanation from the company. Of course when these people were hired the paid pumpers were loud about how awesome and significant the hires were and how they'd do great things yada yada yada.

Could Rae be leaving before the fallout from the SEC and DOJ investigation results being released? Who the heck wants to associate their name with Naddir Pourhassin?

His was a rational analysis based on facts. On the other hand, pumpers say wildly speculative nonsense like "GSK partnership", "buyout imminent" with no basis in reality, yet taken by most here as true.

Brandon Rae leaves Cytodyn. The pumpers already saying no big deal, what did he ever accomplish. The same pumpers that praised him when he was hired saying "oh look who they hired, acquisitions and partnerships coming!". Looks like Rae accomplished nothing, other than drawing a paycheck as per the norm in CYDY land.

If you read the flurry of twitter activity in the last few days someone posted screenshots of SEC docs showing when Naydenov and Colachis(sp?) placed some buys that helped drive up the price and which Mulholland sold his shares into. I'm sure all 3 never talked though about this right?

I hope you informed the SEC of what you have said in the past about Mulholland, Tony Migs, Nodder, and Amarex.

Scott Kelly drawing a hefty salary for doing nothing and shamefully hiding behind "NDA" bs when asked who exactly is he talking to about partnerships is the biggest joke. That clown found a life of luxury and ease at Cytodyn compared to when he was practicing medicine. If you look at his wife's bio she brags about graduating from an exclusive private high school in Atlanta and also sending their daughters there. Upper class lifestyle takes lots of $$$$ to maintain....guess who's paying for it?

Fully expect all the creditors to swoop in and demand payment for outstanding debts once those 350M shares are sold to suckers. Does anyone think Samsung and Fife are going to sit around and watch CYDY management pay itself with those fresh funds?

CYDY's accounting firm states "In our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of May 31, 2022, based on the COSO criteria." p.58

They are patting themselves on the back for submitting the easy parts of the BLA nearly 1 year ago. No progress on that pesky final portion that is difficult.

$4.2M in cash and $123M in short term liabilities. Ouch.

Sure looks like the SEC and DOJ investigations are ongoing as the company is paying legal fees for them and calls them "investigations":

G&A expenses totaled approximately $44.3 million and $34.3 million during the fiscal years ended May 31, 2022 and 2021, respectively, representing an increase of approximately $10.0 million, or 29% over the previous fiscal year. The increase in G&A expenses over the 2021 fiscal year was primarily due to legal and consulting fees and increased insurance premiums, offset by decreases in salaries, benefits, and stock-based compensation. The increase in legal fees was related to the proxy contest and related lawsuits, SEC and DOJ investigations, the Pestell employment dispute, and the Amarex dispute. [p. 42]

Yeah right. "May" is just the company covering itself from legal liability. When has the company ever delivered on any of its "may", "possibly", etc statements?

SEC and DOJ investigations still going. This time they added the bit about the 2nd FDA warning letter. Nothing to indicate anything's settled or resolved. When that axe drops it won't be pretty. $21.9M in legal fees too!

10K is out. $73.5M inventory write off. Remaining leronlimab expires in 2026 but they stated they don't expect approvals by then. Nadir's $100M foolish escapade. Did the Samsung CEO call to congratulate them on the write off?

None of that matters if an accounting firm is not willing to risk its reputation by signing off on SEC documents it does not have faith in.

If they don't file it by the 15th, most likely the SEC will halt trading of the stock. You can't file an NT 10K and ask for another extension.

Scott Kelly's new book "Observations from a life lived in medicine" is releasing today! Wouldn't a better title have been "Observations while I count your money"?